Skip to search formSkip to main contentSkip to account menu

GDC-0810

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
2018
2018
Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927
Breast cancer is the most frequently diagnosed cancer among women and remains the second leading cause of cancer death in women… 
2018
2018
Abstract NG05: Not all “SERDs” are equal: Context-independent ER degradation and full ER antagonism define the next generation of ER therapeutics
At least eight new molecular entities targeting the Estrogen Receptor (ER) have recently entered clinical development for ER… 
2018
2018
Abstract SY01-01: Endocrine resistance in metastatic breast cancer: Mechanisms and new therapeutic strategies
Multiple lines of preclinical and clinical evidence suggest a continued, albeit altered, role of estrogen receptor (ER) in… 
2018
2018
Effect of Microenvironmental pH Modulation on the Dissolution Rate and Oral Absorption of the Salt of a Weak Acid – Case Study of GDC-0810
The purpose of this work is to investigate the effect of microenvironmental pH modulation on the in vitro dissolution rate and… 
2017
2017
Abstract P3-03-08: A large-scale functional screen to identify resistance mechanisms to selective estrogen receptor degraders fulvestrant and GDC-810 in ER+ breast cancer
Therapies that target the estrogen receptor provide clinical benefit and improved survival for patients with estrogen receptor… 
2016
2016
Abstract 1803: Breast cancer cell lines with acquired resistance to selective ERα degraders (SERDs) are dependent on PI3K signaling
Estrogen positive (ER+) breast cancer accounts for the majority of all breast cancers and is primarily treated with endocrine… 
2016
2016
In vitro drug–drug interaction assessment of GDC-0810, a novel and potent selective estrogen receptor degrader (SERD)
2015
2015
Validation of target engagement using 18F-fluoroestradiol PET in patients undergoing therapy with selective estrogen receptor degrader, ARN-810 (GDC-0810)
2015
2015
Abstract 5053: Discovery of GDC-0810 a novel, non-steroidal selective estrogen receptor degrader with robust activity in pre-clinical models of endocrine-resistant breast cancer
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA The majority of breast cancers express estrogen… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)